2017 / 05

Next Paper
DOI: 10.24075/brsmu.2017-05-06

ORIGINAL RESEARCH

The role of immunological memory in establishing antitumor immunity in patients with ovarian cancer undergoing neoadjuvant therapy

Zlatnik EYu1, Nerodo GA2, Ardzha AYu2, Seliutina ON1, Bondarenko ES1
About authors

1 Laboratory for Immunophenotyping of Tumors,
Rostov Research Institute of Oncology, Rostov-on-Don, Russia

2 Department of Gynecologic Oncology,
Rostov Research Institute of Oncology, Rostov-on-Don, Russia

Correspondence should be addressed: Elena Zlatnik
14-ya liniya, d. 63, Rostov-on-Don, Russia, 344037; ur.liam@kintalz-anele

About paper

Contribution of the authors to this work: Zlatnik EYu — processing and analysis of results of immunological tests, drafting of a manuscript, correspondence with editors; Nerodo GA — research planning, medical supervision, surgical operations and treatment of the patients, data analysis and interpretation; Ardzha AYu — analysis of literature, data collection and analysis, medical supervision; Seliutina ON, Bondarenko ES — immunological tests.

Received: 2017-09-22 Accepted: 2017-09-30 Published online: 2018-01-14
|
Fig. 1. Peripheral blood Tm, flow cytometry: (A) — lymphocyte region among blood cells; (B) — T-lymphocytes population; (C) — distribution of CD4 and CD8; (D) — distribution of CD45RA and CD45RO after logical restriction by CD4; (E) — distribution of CD45RA and CD45RO after logical restriction by CD8; (F) — distribution of CD45RA and CD62L after logical restriction by CD4; (G) — distribution of CD45RA and CD62L after logical restriction by CD8
Fig. 2. AF Tm, flow cytometry: (A) — lymphocytes region; (B) — T-lymphocytes population; (C) — distribution of CD4 and CD8; (D) — distribution of CD45RA and CD45RO after logical restriction by CD4; (E) — distribution of CD45RA and CD45RO after logical restriction by CD8; (F) — the distribution of CD45RA and CD62L after logical restriction by CD4; (G) — distribution of CD45RA and CD62L after logical restriction by CD8
Fig. 3. Tem / Tcm ratio in CD4+ and CD8+ subpopulations of memory T-cells
Fig. 4. Changes in Tm/Th0 ratio, CD4+ and CD8+ subpopulations, blood of OC patients before and after treatment
Table 1. Tm and Th0 subpopulations of CD4+ and CD8+ in blood and AF of OC patients
Note. * — significant differences from blood of healthy donors (p < 0.05); ** — significant differences from blood of patients (p < 0.05). Hereinafter, in tables 2–4 reliability of the differences was calculated through the Wilcoxon test.
Table 2. Central and effector Tm with CD4+ and CD8+ phenotype in blood and AF of OC patients
Note. * — significant differences from AF (р < 0.05).
Table 3. Dynamics of Tm and Th0 levels, blood of OC patients, treatment and control groups
Note. * — significant differences from the parameters of the treatment group after full ChIT course (p < 0.05).
Table 4. Dynamics of Tcm and Tem levels, blood of OC patients, treatment and control groups
Note. * — significant differences from values seen before treatment (p < 0.05); ** — significant differences from the corresponding values of the control group (p < 0.05).